Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Klopp John Michael	2. Date of Event Requiring Statement (MM/DD/YYYY) 9/18/2019	3. Issuer Name and Ticker or Trading Symbol Acer Therapeutics Inc. [ACER]
(Last)        (First)        (Middle) C/O ACER THERAPEUTICS INC., ONE GATEWAY CENTER, SUITE 351	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Technology Officer /
(Street) NEWTON, MA 02458       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	(1)	1/15/2028	Common Stock	25000	$18.48	D
Employee Stock Option (right to buy)	(2)	2/1/2029	Common Stock	11000	$24.46	D

Explanation of Responses:
(1)	The option vests and becomes exercisable over four years as follows: 25% of the shares vested on 01/15/2019, and 1/16th of the shares vest each quarter thereafter for the remaining three years.
(2)	The option vests and becomes exercisable over four years as follows: 25% of the shares vested on 02/01/2020, and 1/16th of the shares vest each quarter thereafter for the remaining three years.

Remarks: Exhibit List: Exhibit 24 Confirming Statement

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Klopp John Michael C/O ACER THERAPEUTICS INC. ONE GATEWAY CENTER, SUITE 351 NEWTON, MA 02458			Chief Technology Officer

Signatures
/s/ Harry Palmin, Attorney-in-fact		9/25/2019
**Signature of Reporting Person		Date